The Top Cap 2026 Is Here! Cast Your Vote

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

123.89 +3.73 (+3.10%)
Streaming Delayed Price Updated: 2:44 PM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
From Incyte and Enable Injections
Via Business Wire
News headline image
What To Expect From Incyte’s (INCY) Q3 Earnings
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know. 
Via StockStory
News headline image
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis ↗
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth. 
Via Benzinga
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals ↗
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
News headline image
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
News headline image
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
News headline image
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
What 14 Analyst Ratings Have To Say About Incyte ↗
 
Via Benzinga
News headline image
Which S&P500 stocks are gapping on Wednesday? ↗
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index. 
Via Chartmill
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
2 Reasons to Like INCY and 1 to Stay Skeptical
Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly... 
Via StockStory
Topics Stocks
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
News headline image
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market ↗
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs. 
Via Benzinga
Topics Stocks
News headline image
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
News headline image
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) ↗
 
Via Benzinga
News headline image
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children ↗
FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens and adults. 
Via Benzinga
News headline image
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate ↗
Incyte Corp (INCY) presents a strong value investing case with low P/E ratios, robust financial health, and high profitability in the biotech sector. 
Via Chartmill
News headline image
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
News headline image
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
3 Unpopular Stocks That Deserve a Second Chance
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire
News headline image
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article